Abstract
The prevalence rate and clinical significance of the metabolic syndrome in type 1
diabetic patients are not well established. The aim of this study was to estimate
the prevalence rate of the metabolic syndrome in adult patients with type 1 diabetes.
Patients with type 1 diabetes (n=533; age: 35.6±11.6 years; duration of diabetes:
18.0±11.1 years; x±SD) were consecutively enrolled from 11 diabetes outpatient departments.
Data on medical history, actual treatment, anthropometric and laboratory parameters
as well as actual blood pressure were registered while eating habits and physical
activity were evaluated by standardized questionnaires. The prevalence rate of the
metabolic syndrome according to the ATP-III criteria was 31.1% (29.7% in men, 32.7%
in women; p>0.05). Using the IDF criteria a higher overall prevalence rate of the
metabolic syndrome (36.2%; [32,8% in men, 39.4% in women; p>0.05]) was observed. Comparing
type 1 diabetic patients to the general population, the prevalence rate of the metabolic
syndrome proved to be significantly higher in each age-group of patients with type
1 diabetes. According to the stepwise logistic regression analysis the metabolic syndrome
in type 1 diabetic patients was associated in a decreasing ranking order of significance
with waist circumference, serum triglycerides, female gender, antihypertensive medication,
HDL-cholesterol, diastolic blood pressure and serum creatinine.
Conclusions: The metabolic syndrome can frequently be detected and is predominantly associated
with higher waist circumference in adult patients with type 1 diabetes in Hungary.
Key words
metabolic syndrome - type 1 diabetes - cardiovascular risk factor - waist circumference
- abdominal obesity
References
1
Alberti KGMM, Zimmet P, Shaw J.
The metabolic syndrome – a new worldwide definition.
Lancet.
2005;
366
1059-1062
2
Bonora E.
The metabolic syndrome and cardiovascular disease.
Ann Med.
2006;
38
64-80
3
Cockcroft D, Gault MD.
Prediction of creatinine clearance from serum creatinine.
Nephron.
1976;
16
31-41
4
Davis TM, Bruce DG, Davis WA.
Prevalence and prognostic implications of the metabolic syndrome in community-based
patients with type 1 diabetes: the Fremantle Diabetes Study.
Diabetes Res Clin Pract.
2007;
78
412-417
5
DeFronzo RA, Hendler R, Simonson D.
Insulin resistance is a prominent feature of insulin-dependent diabetes.
Diabetes.
1982;
31
795-801
6
Després JP.
Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular
disease.
J Endocrinol Invest.
2006;
29
77-82
7
Després JP, Lemieux I.
Abdominal obesity and metabolic syndrome.
Nature.
2006;
444
881-887
8
Expert panel on detection, evaluation, and treatment of high blood cholesterol in
adults
.
Executive summary of the third report of the National Cholesterol Education Program
(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol
in adults (Adult Treatment Panel III).
JAMA.
2001;
285
2486-2497
9
Ford ES.
Risks for all-cause mortality, cardiovascular disease, and diabetes associated with
the metabolic syndrome: a summary of the evidence.
Diabetes Care.
2005;
28
1769-1778
10
Ford ES, Giles WH, Dietz WH.
Prevalence of the metabolic syndrome among US adults: findings from the third National
Health and Nutrition Examination Survey.
JAMA.
2002;
287
356-359
11
Ford ES, Li C.
Physical activity or fitness and the metabolic syndrome.
Expert Rev Cardiovasc Ther.
2006;
4
897-915
12
Friedewald WT, Levy RI, Fredrickson DS.
Estimation of the concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge.
Clin Chem.
1972;
18
499-502
13
Jermendy Gy, Hetyési K, Bíró L. et al .
Prevalence of the metabolic syndrome in hypertensive and/or obese subjects.
Diabetic Med.
2004;
21
805-806
14
Kahn R, Buse J, Ferrannini E. et al .
The metabolic syndrome: time for a critical appraisal. Joint statement from the American
Diabetes Association and the European Association for the Study of Diabetes.
Diabetologia.
2005;
48
1684-1699
15
Kilpatrick ES, Rigby AS, Atkin SL.
Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes:
“double diabetes” in the Diabetes Control and Complications Trial.
Diabetes Care.
2007;
30
707-712
16
Lakka HM, Laaksonen DE, Lakka TA. et al .
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged
men.
JAMA.
2002;
288
2709-2716
17
Lorenzo C, Williams K, Hunt KJ. et al .
The National Cholesterol Education Program – Adult Treatment Panel III, International
Diabetes Federation, and World Health Organization definitions of the metabolic syndrome
as predictors of incident cardiovascular disease and diabetes.
Diabetes Care.
2007;
30
8-13
18
Maison P, Byrne CD, Hales CN. et al .
Do different dimensions of the metabolic syndrome change together over time? Evidence
supporting obesity as the central feature.
Diabetes Care.
2001;
24
1758-1763
19
Metascreen Writing Committee
.
The metabolic syndrome is a risk indicator of microvascular and macrovascular complications
in diabetes. Results form Metascreen, a multicenter diabetes clinic-based survey.
Diabetes Care.
2006;
29
2701-2707
20
Nádas J, Putz Zs, Jermendy Gy. et al .
Public awareness of the metabolic syndrome.
Diab Res Clin Pract.
2007;
76
155-156
21
Pambianco G, Costacou T, Orchard TJ.
The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation
of three separate definitions of the metabolic syndrome and their components and estimated
glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study
experience.
Diabetes Care.
2007;
30
1248-1254
22
Reaven GM.
The role of insulin resistance in human disease.
Diabetes.
1988;
37
1595-1607
23
Reindel J, Zander E, Heinke P. et al .
The metabolic syndrome in patients with type 1 diabetes mellitus: Associations with
cardiovascular risk factors and cardiovascular morbidity.
Herz.
2004;
29
463-469
24
Smith SC JR, Haslam D.
Abdominal obesity, waist circumference and cardio-metabolic risk: awareness among
primary care physicians, the general population and patients at risk – the Shape of
the Nation survey.
Curr Med Res Opin.
2007;
23
29-47
25
Széles G, Szigethy E, Vokó Z. et al .
The epidemiology of metabolic syndrome in the Hungarian adult population: a representative
survey (abstract).
Diabetes Care.
2007;
56
((Suppl 1))
A626
26
Teupe B, Bergis K.
Epidemiological evidence for “double diabetes”.
Lancet.
1991;
337
361-362
27
The DCCT Research Group
.
Weight gain associated with intensive therapy in the Diabetes Control and Complications
Trial.
Diabetes Care.
1988;
11
567-573
28
Thorn LM, Forsblom C, Fagerudd J. et al .
Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic
control (the FinnDiane study).
Diabetes Care.
2005;
28
2019-2024
29
Vargane HP, Adany R.
Trends of premature mortality from cardiovascular diseases in Hungary and the European
Union, 1970–1997.
Orv Hetil.
2000;
141
601-607
30
Yusuf S, Hawken S, Ounpuu S. et al .
Obesity and the risk of myocardial infarction in 27.000 participants from 52 countries:
a case-control study.
Lancet.
2005;
366
1640-1649
Notice
The original article with DOI number 10.1055/s-0028-1082088 has been corrected in
accordance with the following Erratum on February 15th 2010. The correct DOI number
is 10.1055/s-0028-1082068
Erratum
Please note: in this article several spelling mistakes were corrected after e-first
online publication.
Correspondence
G. Jermendy
Bajcsy-Zsilinszky Teaching Hospital
Medical Department
Maglódi út 89-91
1106 Budapest
Hungary
Phone: +36/1/432 75 33
Fax: +36/1/432 75 33
Email: gyjermendy@mail.datanet.hu